Cargando…

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brazel, Danielle, Ou, Sai-Hong Ignatius, Nagasaka, Misako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831070/ https://www.ncbi.nlm.nih.gov/pubmed/36636263 http://dx.doi.org/10.2147/LCTT.S379389

Ejemplares similares

Thermodynamics of Tower-Block Infernos: Effects of Water on Aluminum Fires
por: Maguire, John F., et al.
Publicado: (2019)

Skyscrapers /
por: Dupré, Judith

Skyscrapers : the new millennium /
Publicado: (2000)

Manhattan skyscrapers
por: Nash, Eric Peter
Publicado: (1999)

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
por: Kim, Tae Won, et al.
Publicado: (2023)

Inferno
por: Brown, Dan, 1964-
Publicado: (2013)

Inferno
por: Strindberg, August, 1849-1912
Publicado: (1997)

Inferno
por: Reeves-Stevens, Judith
Publicado: (2000)

Inferno
por: Strindberg, August, 1849-1912
Publicado: (1978)

The inferno
por: Hoyle, Fred, et al.
Publicado: (1973)

The inferno /
por: Dante Alighieri, 1265-1321
Publicado: (1954)

Inferno
por: Petersen, Eskild
Publicado: (2013)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2021)

The green skyscraper : the basis for designing sustainable intensive buildings
por: Yeang, Ken, 1948-
Publicado: (1999)

Increasing Skyscrapers: Possibility of New Disaster
por: CHO, Kwang Rae, et al.
Publicado: (2014)

Why skyscrapers after Covid-19?
por: Smith, Richard G.
Publicado: (2021)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

The development of amivantamab for the treatment of non-small cell lung cancer
por: Brazel, Danielle, et al.
Publicado: (2023)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
por: Nagasaka, Misako, et al.
Publicado: (2022)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Una temporada en el inferno
por: Rimbaud, Arthur, 1854-1891

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Granite skyscrapers: how rock shaped earth and other worlds
por: Stevenson, David S
Publicado: (2018)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

INFERNO: inferring the molecular mechanisms of noncoding genetic variants
por: Amlie-Wolf, Alexandre, et al.
Publicado: (2018)

Fast and accurate influenza forecasting in the United States with Inferno
por: Osthus, Dave
Publicado: (2022)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Multilayered skyscraper microchips fabricated by hybrid “all-in-one” femtosecond laser processing
por: Wang, Chaowei, et al.
Publicado: (2019)

Iterative free-energy optimization for recurrent neural networks (INFERNO)
por: Pitti, Alexandre, et al.
Publicado: (2017)

iDISCO Inferno: Mapping Connectivity Changes Following TBI
por: Lau, Lauren A., et al.
Publicado: (2023)

In Response to Dr. Steven Sorscher
por: Zhang, Shannon S., et al.
Publicado: (2022)

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
por: Roussot, Nicolas, et al.
Publicado: (2023)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

The sensory pain of Dante's Inferno - Semantics of chronic pain in patients with narcolepsy
por: Cremaschi, Renata Carvalho, et al.
Publicado: (2019)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_343lutme0isosahlna0svj70d7